Solving COVID: October 14, 2020
Inhaled vaccines are under development, Eli Lilly pauses its treatment trial, and more
- 1. Inhaled coronavirus vaccines are under development — and could be more effective than an injection
- 2. U.S. health regulators pause Eli Lilly's coronavirus treatment trials
- 3. 86 percent of people with coronavirus cases in the U.K. showed no major symptoms
- 4. Study finds coronavirus can survive on smooth surfaces for 28 days
- 5. U.K. vaccine chief says COVID-19 vaccine may be 50 percent effective
1. Inhaled coronavirus vaccines are under development — and could be more effective than an injection
Dozens of COVID-19 vaccines are under development worldwide, with the ones closest to ready for public use being traditional, injectable vaccines. But scientists in the U.S., the U.K., and Hong Kong are working on an alternative: inhaled vaccines. Most of the injected vaccines in testing would require multiple shots to be effective, and it's not even clear if COVID-19 antibodies will prevent an infection. Meanwhile scientists have hypothesized inhaled immunizations could be more effective than injections because they could stop the coronavirus at the place it's often contracted: the nose. Stopping the virus' growth in the nose could then prevent its transmission. In addition, the respiratory system is full of immune system protections that an inhaled vaccine could bolster.
South China Morning Post Bloomberg
2. U.S. health regulators pause Eli Lilly's coronavirus treatment trials
Federal health regulators paused enrollment in trials of Eli Lilly's coronavirus antibody treatment on Tuesday "out of an abundance of caution." Officials did not explain why the pause was recommended, but Dr. Carlos del Rio, an infectious diseases expert at Emory University School of Medicine, told NBC News that "pauses are not infrequent in a clinical trial." The decision comes after Johnson & Johnson paused its coronavirus vaccine trial due to an "unexplained illness." Last week, Eli Lilly said it would soon request emergency authorization for another antibody treatment it had developed. The treatment paused Tuesday was determined to reduce patients' COVID-19 viral load and help them avoid hospitalization. It's similar to the treatment from Regeneron given to President Trump.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
3. 86 percent of people with coronavirus cases in the U.K. showed no major symptoms
A survey conducted by the U.K.'s Office for National Statistics revealed 86.1 percent of people who contracted COVID-19 between April and June showed no major symptoms of the disease, including cough, fever, or a loss of taste or smell, on the day they were tested. Around three quarters of those tested showed no symptoms at all, including fatigue or a shortness of breath. Due to a undersupply of tests, health officials have only suggested getting tested for coronavirus if one shows symptoms or has been around someone with the virus. But with most people asymptomatic, the virus could spread widely without detection before people show severe symptoms. The ONS tested 36,000 people for the coronavirus, with 115 cases coming back positive.
4. Study finds coronavirus can survive on smooth surfaces for 28 days
In a study published Monday in Virology Journal, researchers at CSIRO, Australia's national science agency, write that they found at 68 degrees Fahrenheit, the SARS-COV-2 virus can stay infectious for 28 days on smooth surfaces. This is a longer amount of time than the Influenza A virus remains on surfaces; it's been found to survive for 17 days. During their research, scientists dried the coronavirus in an artificial mucus and placed it on different surfaces in concentrations similar to samples gathered by COVID-19 patients, and then returned a month later to extract the virus, Reuters reports. They conducted their experiments in a lab, and found that the higher the temperature, the lower the survival time of the virus. In a statement, CSIRO Chief Executive Larry Marshall said "establishing how long the virus really remains viable on surfaces enables us to more accurately predict and mitigate its spread and do a better job of protecting our people."
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
5. U.K. vaccine chief says COVID-19 vaccine may be 50 percent effective
The first wave of COVID-19 vaccines probably won't end the coronavirus pandemic, but "a partially effective vaccine is better than no vaccine at all," Kate Gingham, the head of Britain's vaccine task force, told Sky News. "Flu vaccines are 50 percent effective, but they are widely used and have a big impact on reducing the clinical impacts of flu in the population." She told The Telegraph that with the COVID-19 effort, "we shouldn't assume it's going to be better than a flu vaccine." In the U.S., the Food and Drug Administration won't approve any COVID-19 vaccine that is less that 50 percent effective at preventing infection or reducing severity, but Moncef Slaoui, chief scientific adviser to the U.S. government's Operation Warp Speed vaccine initiative, predicted at least some of the dozen vaccines under development will be 75 to 90 percent effective.
Create an account with the same email registered to your subscription to unlock access.
-
The Pélicot case: a horror exposed
Talking Point This case is unusually horrifying, but the misogyny that enabled is chillingly common
By The Week UK Published
-
Beetlejuice Beetlejuice: pure 'nostalgia bait'
Talking Point Michael Keaton and Winona Ryder return for sequel to the 1988 cult classic
By The Week UK Published
-
Crossword: September 14, 2024
The Week's daily crossword puzzle
By The Week Staff Published
-
A brief history of third parties in the US
In Depth Though none of America's third parties have won a presidential election, they have nonetheless had a large impact on the country's politics
By Joel Mathis, The Week US Published
-
Chimpanzees are dying of human diseases
Under the radar Great apes are vulnerable to human pathogens thanks to genetic similarity, increased contact and no immunity
By Harriet Marsden, The Week UK Published
-
Deaths of Jesse Baird and Luke Davies hang over Sydney's Mardi Gras
The Explainer Police officer, the former partner of TV presenter victim, charged with two counts of murder after turning himself in
By Austin Chen, The Week UK Published
-
Quiz of The Week: 24 February - 1 March
Puzzles and Quizzes Have you been paying attention to The Week's news?
By Sorcha Bradley, The Week UK Published
-
Will mounting discontent affect Iran election?
Today's Big Question Low turnout is expected in poll seen as crucial test for Tehran's leadership
By Sorcha Bradley, The Week UK Published
-
Sweden clears final NATO hurdle with Hungary vote
Speed Read Hungary's parliament overwhelmingly approved Sweden's accession to NATO
By Peter Weber, The Week US Published
-
Modern royal scandals from around the world
The Explainer From Spain to the UAE, royal families have often been besieged by negative events
By Justin Klawans, The Week US Published
-
Zelenskyy says 31,000 troops dead in 2 years of war
Speed Read Ukrainian President Volodymyr Zelenskyy gave a rare official military death toll
By Peter Weber, The Week US Published